Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis
Authors:
- 12 February 2019
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (6) , 1587-1594
Abstract
Objectives To investigate the effective serum level of etanercept biosimilar in Chinese patients with ankylosing spondylitis (AS) who achieve AS Disease Activity Score-C-reactive protein (ASDAS-CRP) < 2.1, and the effect of antidrug antibodies on drug levels and clinical efficacy. Methods Our study enrolled 60 patients with AS who were treated with etanercept biosimilar. Serum and clinical data were collected at baseline and treatment weeks 4, 12, and 24. Drug levels and antidrug antibody levels were measured using an enzyme-linked immunosorbent assay while tumour necrosis factor (TNF)-α levels were measured using cytometric bead array. A receiver operating characteristic (ROC) curve was used to analyse effective serum level of etanercept biosimilar. Results Patients with ASDAS-CRP ≥ 2.1 exhibited significantly lower drug levels than those with ASDAS-CRP < 2.1 did. The cut-off values of effective serum level of patients with AS who achieved ASDAS-CRP < 2.1 at weeks 4, 12, and 24 were 2.32, 2.12, and 2.36 μg/mL, respectively. Patients with drug levels above the cut-off value had lower Bath AS Disease Activity Index (BASDAI) and TNF-α levels. Antidrug antibodies had no effect on the Assessment of Spondylosis Arthritis International Society (ASAS) remission rates, but patients with antidrug antibodies had lower drug levels and higher TNF-α levels. Conclusions Detecting serum drug levels and antidrug antibody levels might facilitate estimation of the clinical efficacy and adjustment of medication regimen during etanercept biosimilar therapy in Chinese patients with AS.Keywords
Funding Information
- National Key Research and Development Program of China (No. 2017YFC0909002)
This publication has 27 references indexed in Scilit:
- Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patientsClinical Rheumatology, 2013
- Can we reduce the dosage of biologics in spondyloarthritis?Autoimmunity Reviews, 2013
- Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formationAnnals of the Rheumatic Diseases, 2009
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitionsAnnals of the Rheumatic Diseases, 2008
- Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2008
- Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formationAnnals of the Rheumatic Diseases, 2007
- Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984